McKesson to Distribute Future COVID-19 Vaccines in Support of Operation Warp Speed
August 14 2020 - 12:59PM
Business Wire
The Centers for Disease Control is Exercising
an Option of an Existing Contract with McKesson for This Effort
A global leader in the healthcare industry, McKesson Corporation
(NYSE: MCK) will expand its existing partnership with the Centers
for Disease Control (CDC) to support the U.S. government’s
Operation Warp Speed (OWS) team as a centralized distributor of
future COVID-19 vaccines and ancillary supplies needed to
administer vaccinations. Vaccines and related supplies will be
delivered to point-of-care sites across the country at the U.S.
government’s direction.
“McKesson is committed to supporting public health in the U.S.
and around the world,” said Brian Tyler, CEO of McKesson. “Since
the onset of the pandemic, McKesson has leveraged our deep
expertise to help maintain the integrity of the healthcare supply
chain, source and distribute personal protective equipment to
frontline workers and stand up COVID-19 testing at Health Mart
pharmacies, many in underserved communities. We are honored that
the U.S. government has asked McKesson to play a key role in the
effort to distribute COVID-19 vaccines.”
The CDC has an existing contract with McKesson to support
distribution as part of the CDC’s Vaccines for Children Program
(VFC). This contract was awarded to McKesson in a competitive
bidding process initiated in 2016 and includes an option for
distribution of vaccines in the event of a pandemic. McKesson will
utilize its expertise and capabilities, along with other industry
partners, to support the CDC’s efforts to vaccinate everyone in the
U.S. who wants to receive a COVID-19 vaccine. CDC and McKesson
collaborated similarly in response to the H1N1 pandemic.
Beyond programs with the CDC, McKesson is the largest seasonal
flu vaccine distributor in the U.S. and distributes up to 150
million doses of all vaccines annually to public health clinics,
hospitals, physician offices, nursing homes, pharmacies and other
care facilities.
Cautionary Statements
Except for historical information, statements in this press
release may constitute “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, that involve risks and
uncertainties that could cause actual results to differ materially
from those in those statements. It is not possible to identify all
such risks and uncertainties. Forward-looking statements may be
identified by their use of terminology such as “will” or their
references to future events, such as delivery of vaccines to
point-of-care sites and support of CDC efforts. The reader should
not place undue reliance on forward-looking statements, such as
financial performance forecasts, which speak only as of the date
they are first made. Except to the extent required by law, the
company undertakes no obligation to publicly update forward-looking
statements. We encourage investors to read the important risk
factors described in the company’s Form 10-K, Form 10-Q and Form
8-K reports filed with the Securities and Exchange Commission.
These risk factors include, but are not limited to: our
contracts with government entities involve future funding and
compliance risks; we might be harmed by changes in our
relationships or contracts with suppliers; we might be adversely
impacted by changes or disruptions in product supply and we have
experienced and may experience difficulties in sourcing products
due to the effects of the COVID-19 pandemic on supply chains; and
we might be adversely impacted by events outside of our control,
such as widespread public health issues (including the effects we
have experienced from the COVID-19 pandemic), natural disasters,
political events and other catastrophic events.
About McKesson Corporation
McKesson Corporation is a global leader in healthcare supply
chain management solutions, retail pharmacy, community oncology and
specialty care, and healthcare information solutions. McKesson
partners with pharmaceutical manufacturers, providers, pharmacies,
governments and other organizations in healthcare to help provide
the right medicines, medical products and healthcare services to
the right patients at the right time, safely and cost-effectively.
United by our ICARE shared principles, our employees work every day
to innovate and deliver opportunities that make our customers and
partners more successful - all for the better health of patients.
McKesson has been named a “Most Admired Company” in the healthcare
wholesaler category by FORTUNE, a “Best Place to Work” by the Human
Rights Campaign Foundation, and a top military-friendly company by
Military Friendly. For more information, visit
www.mckesson.com.
About Operation Warp Speed
OWS is a partnership among components of the Department of
Health and Human Services and the Department of Defense, engaging
with private firms and other federal agencies, and coordinating
among existing HHS-wide efforts to accelerate the development,
manufacturing, and distribution of COVID-19 vaccines, therapeutics,
and diagnostics.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200814005428/en/
Holly Weiss, 972-969-9174 (Investors) Holly.Weiss@McKesson.com
David Matthews, 214-952-0833 (Media)
David.Matthews@McKesson.com
McKesson (NYSE:MCK)
Historical Stock Chart
From Apr 2024 to May 2024
McKesson (NYSE:MCK)
Historical Stock Chart
From May 2023 to May 2024